Almac Announces Expansion to its Commercial Facility with the Addition of Increased Storage Capacity for Biologic Products
In response to increased client demand for cold and dedicated frozen storage capacity for biopharmaceuticals, Almac’s Pharma Services business unit has expanded its commercial facilities to include an additional 6,124 sq ft of cold and frozen storage.
This is a joint investment with a commercial client, for which Almac provides central EU importation, warehousing and distribution services. This includes dedicated -70°C, -20°C and 2-8°C storage for drug antibody, drug linker, bulk drug substance, placebo and filled vials, coupled to before and after distribution to various global processing facilities.
In preparation for the successful commercialisation of the drug product, 20 additional dedicated freezer units have been added to the existing 10, for the storage of the monoclonal antibody and bulk drug substance products.
Strengthening Almac’s EU product launch services, the expansion has also resulted in increased floor space facilitating shipping system configuration for bulk drug product and for direct to pharmacy supply of niche orphan drug products.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
